allergan irvine

Allergan | Cenicriviroc

Allergan picked up its lead NASH program, cenicriviroc, in its 2016 acquisition of Tobira Therapeutics, just after it failed a phase 2b NASH study. With regulators’ support, Tobira retooled the endpoint for the phase 3 study, which Allergan is carrying forward.